Literature DB >> 31111878

Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors.

G Marcucci1, G Beltrami2, A Tamburini3, J J Body4, C B Confavreux5, P Hadji6, G Holzer7, D Kendler8, N Napoli9,10, D D Pierroz11, R Rizzoli12, M L Brandi1.   

Abstract

In the past decades, new cancer treatment approaches for children and adolescents have led to a decrease in recurrence rates and an increase in long-term survival. Recent studies have focused on the evaluation of the late effects on bone of pediatric cancer-related treatments, such as chemotherapy, radiation and surgery. Treatment of childhood cancer can impair the attainment of peak bone mass, predisposing to premature onset of low bone mineral density, or causing other bone side-effects, such as bone quality impairment or avascular necrosis of bone. Lower bone mineral density and microarchitectural deterioration can persist during adulthood, thereby increasing fracture risk. Overall, long-term follow-up of childhood cancer survivors is essential to define specific groups at higher risk of long-term bone complications, identify unrecognized long-term adverse effects, and improve patient care. Children and adolescents with a cancer history should be carefully monitored, and patients should be informed of possible late complications of their previous medical treatment. The International Osteoporosis Foundation convened a working group to review the bone complications of pediatric cancer survivors, outlining recommendations for the management of bone health, in order to prevent and treat these complications.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  chemotherapy; childhood cancer; childhood cancer survivor; osteonecrosis; osteoporosis; radiotherapy

Year:  2019        PMID: 31111878     DOI: 10.1093/annonc/mdz120

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  13 in total

Review 1.  Endogenous repair theory enriches construction strategies for orthopaedic biomaterials: a narrative review.

Authors:  Yizhong Peng; Jinye Li; Hui Lin; Shuo Tian; Sheng Liu; Feifei Pu; Lei Zhao; Kaige Ma; Xiangcheng Qing; Zengwu Shao
Journal:  Biomater Transl       Date:  2021-12-28

Review 2.  Bone Health Issues in the Pediatric Oncology Patient.

Authors:  Paulette M Kelly; Elaine Pottenger
Journal:  Semin Oncol Nurs       Date:  2022-04-28       Impact factor: 3.527

3.  Psoralen alleviates radiation-induced bone injury by rescuing skeletal stem cell stemness through AKT-mediated upregulation of GSK-3β and NRF2.

Authors:  Bo-Feng Yin; Zhi-Ling Li; Zi-Qiao Yan; Zheng Guo; Jia-Wu Liang; Qian Wang; Zhi-Dong Zhao; Pei-Lin Li; Rui-Cong Hao; Meng-Yue Han; Xiao-Tong Li; Ning Mao; Li Ding; Da-Fu Chen; Yue Gao; Heng Zhu
Journal:  Stem Cell Res Ther       Date:  2022-06-07       Impact factor: 8.079

Review 4.  The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer.

Authors:  Magdalena Schab; Szymon Skoczen
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

5.  CORR Insights®: Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A Controlled Study at Long-term Follow-up Using High-resolution Peripheral Quantitative CT.

Authors:  Andre Mathias Baptista
Journal:  Clin Orthop Relat Res       Date:  2021-11-01       Impact factor: 4.755

6.  Improving vitamin D testing and supplementation in children with newly diagnosed cancer: A quality improvement initiative at Rady Children's Hospital San Diego.

Authors:  Ksenya Shliakhtsitsava; Erin Stucky Fisher; Erin M Trovillion; Kelly Bush; Dennis John Kuo; Ron S Newfield; Courtney D Thornburg; William Roberts; Paula Aristizabal
Journal:  Pediatr Blood Cancer       Date:  2021-07-19       Impact factor: 3.167

7.  Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.

Authors:  A Deodati; D Fintini; E Levtchenko; M Rossi; G Ubertini; H Segers; G Battafarano; M Cappa; A Del Fattore
Journal:  J Endocrinol Invest       Date:  2021-07-03       Impact factor: 4.256

8.  Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations.

Authors:  Jenneke E van Atteveld; Iris E Verhagen; Marry M van den Heuvel-Eibrink; Hanneke M van Santen; Inge M van der Sluis; Natascia Di Iorgi; Jill H Simmons; Leanne M Ward; Sebastian J C M M Neggers
Journal:  Cancer Med       Date:  2021-06-08       Impact factor: 4.452

Review 9.  Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Authors:  Jenneke E van Atteveld; Renée L Mulder; Marry M van den Heuvel-Eibrink; Melissa M Hudson; Leontien C M Kremer; Roderick Skinner; W Hamish Wallace; Louis S Constine; Claire E Higham; Sue C Kaste; Riitta Niinimäki; Sogol Mostoufi-Moab; Nathalie Alos; Danilo Fintini; Kimberly J Templeton; Leanne M Ward; Eva Frey; Roberto Franceschi; Vesna Pavasovic; Seth E Karol; Nadia L Amin; Lynda M Vrooman; Arja Harila-Saari; Charlotte Demoor-Goldschmidt; Robert D Murray; Edit Bardi; Maarten H Lequin; Maria Felicia Faienza; Olga Zaikova; Claire Berger; Stefano Mora; Kirsten K Ness; Sebastian J C M M Neggers; Saskia M F Pluijm; Jill H Simmons; Natascia Di Iorgi
Journal:  Lancet Diabetes Endocrinol       Date:  2021-07-30       Impact factor: 44.867

10.  Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A Controlled Study at Long-term Follow-up Using High-resolution Peripheral Quantitative CT.

Authors:  Gerold Holzer; Gerhard Hobusch; Stinus Hansen; Lukas Fischer; Janina M Patsch
Journal:  Clin Orthop Relat Res       Date:  2021-11-01       Impact factor: 4.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.